SingulaBio

At Singula Bio, we are delighted to be sharing you this recent interview between one of our founders, @ProfAhmedA and none other than leading global biotech company, @miltenyibiotec . Clink the link below to read the full interview with Prof Ahmed! miltenyibiotec.com/GB-en/lp/scien…

Here is a great video created by @OxfordAhmedLab to explain the role of the fallopian tubes in serous ovarian cancer. You can also read more about our findings on the fallopian tubes at single cell level here: cell.com/cancer-cell/pd… @zhi_yuan_hu youtube.com/watch?v=AwKZVE… 3/3

Not even the rain could dampen their spirits! Congratulations to @ProfAhmedA, Joel Nulsen and Lili Wang from the Singula Bio team for taking part in the Oxford Town and Gown run last Sunday to raise money for Muscular Dystrophy UK . Well done, team!

We are delighted to announce that one of our founders, @ProfAhmedA , received a front cover publication in The Journal of Clinical Investigation's JCI insight for his paper on minimal residual disease (MRD). Click the link to read! insight.jci.org/articles/view/…

Singula Bio is #hiring ! We're looking for a full time Senior Scientist in Translational Cancer Immunology to join our growing, international team of translational researchers and immunologists. Clink the link below for more details and to apply! singulabio.com/join-our-team/…

Singula Bio is #hiring ! We're looking for a full time senior scientist in cancer genomics to join our growing, international team of translational researchers and immunologists. Clink the link below to find out more and to apply! singulabio.com/join-our-team/…

.@BioSingula's patient-centred approach will pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer. Learn more: bit.ly/3uu8Poy #WorldHealthDay

We are delighted to welcome our new, Non Executive Director, Dr James Hall. James is currently CEO of Betagenon AB, a Swedish clinical stage biotech. He has also held several senior roles at AstraZeneca and previously worked in the Pharma/Biotech practice at McKinsey & Co.

Part 2 of our interview with Profs @ProfAhmedA and Enda McVeigh. Have a read below to see what sets us apart and how we envisage the future of cancer treatment.

NEWS: @BioSingula, a bold new seed-stage biotechnology @UniofOxford spinout, launched this week. Led by @Ox_wrh cancer specialists it aims to become a world leader in therapies to use against difficult-to-treat solid malignancies, such as ovarian cancer. medsci.ox.ac.uk/news/singula-b…

At Singula Bio, we want to give you the opportunity to get to know us a bit better. We got our founders, Profs Enda McVeigh and @ProfAhmedA , together for an interview to giving you a greater insight into how we started and what we aim to achieve. Stay tuned tomorrow for part 2!

Cancer Need not be Fatal - This is the core mission of @BioSingula - a bold new Oxford spinout launching today! It will draw on a multi-discipline approach for therapies which work with a patient to eliminate cancer. Read more bit.ly/2NQYsel @ProfAhmedA @OxfordMedsci

Our press release is live! Follow the link below to read about our ground-breaking, innovative work in the field of cancer treatment. innovation.ox.ac.uk/news/singula-b…

What does joining Singula Bio mean to you? Joel Nulsen, our new Computational Biology scientist, tells us, "The team pulls together a wealth of experience from across industry, academia and the clinic, and we hope to measure our success in real improvements to patients’ lives."

Breaking down the science! Our immune system reacts to mutations in cancer cells by generating “T cells” to attack them. These T cells can become exhausted and so at Singula Bio, we aim to identify them, expand them outside the body and deliver them back to fight the tumour.